{"id":102,"date":"2026-06-30T15:37:00","date_gmt":"2026-06-30T15:37:00","guid":{"rendered":"https:\/\/heartimed.com\/?p=102"},"modified":"2026-06-30T15:38:07","modified_gmt":"2026-06-30T15:38:07","slug":"blood-pressure-based-on-2025-esc-guideline-for-summary","status":"publish","type":"post","link":"https:\/\/heartimed.com\/?p=102","title":{"rendered":"Blood pressure Based on 2025 ESC Guideline for Summary"},"content":{"rendered":"\n

1. Definition & Classification<\/strong><\/p>\n\n\n\n

The ESC has refined its classification system into three distinct categories based on standardized office blood pressure (BP) measurements<\/strong>.<\/p>\n\n\n\n

Category<\/td>Office Systolic BP (mmHg)<\/td>Office Diastolic BP (mmHg)<\/td>Key Implication<\/td><\/tr><\/thead>
Non-elevated BP<\/strong><\/td>< 120<\/td>and < 70<\/td>Normal range; drug treatment is not recommended.<\/td><\/tr>
Elevated BP<\/strong> (NEW)<\/td>120\u2013139<\/td>or 70\u201389<\/td>A new “pre-hypertensive” state that identifies individuals at risk. Management depends on overall cardiovascular risk.<\/td><\/tr>
Hypertension<\/strong><\/td>\u2265 140<\/td>or \u2265 90<\/td>The definition of hypertension remains unchanged. Confirmation requires out-of-office measurements.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2. Diagnosis<\/strong><\/p>\n\n\n\n

The guidelines strongly emphasize the importance of accurate diagnosis, moving away from reliance on single in-clinic readings.<\/p>\n\n\n\n

    \n
  • Out-of-Office Measurement is Preferred<\/strong>: For diagnosing and managing hypertension,\u00a0ambulatory blood pressure monitoring (ABPM)<\/strong>\u00a0or\u00a0home blood pressure monitoring (HBPM)<\/strong>\u00a0is recommended whenever feasible.<\/li>\n\n\n\n
  • Detecting Phenotypes<\/strong>: Out-of-office measurements are crucial for identifying:\n
      \n
    • White-coat hypertension<\/strong>: High BP in the clinic but normal outside.<\/li>\n\n\n\n
    • Masked hypertension<\/strong>: Normal BP in the clinic but high outside.<\/li>\n<\/ul>\n<\/li>\n\n\n\n
    • In-Clinic Measurement<\/strong>: If out-of-office readings are not possible, standardized office measurements can be used. It is important to note that routine office BP may be 5\u201310 mmHg higher than standardized readings.<\/li>\n\n\n\n
    • Special Circumstance<\/strong>: In patients with\u00a0atrial fibrillation<\/strong>, manual BP measurements are recommended as most automated devices are not validated for this condition.<\/li>\n<\/ul>\n\n\n\n

      3. Initial Investigation & Risk Assessment<\/strong><\/p>\n\n\n\n

      Upon diagnosis, a comprehensive assessment is vital to guide management. This involves evaluating:<\/p>\n\n\n\n

        \n
      • Causative and Contributory Factors<\/strong>: Lifestyle, medications, and potential secondary causes.<\/li>\n\n\n\n
      • Cardiovascular Disease (CVD) Risk<\/strong>: A stepwise approach is recommended for all individuals with elevated BP:\n
          \n
        1. Assess for high-risk conditions (e.g., established CVD, diabetes, chronic kidney disease).<\/li>\n\n\n\n
        2. Predict 10-year CVD risk using tools like\u00a0SCORE2<\/strong>\u00a0or\u00a0SCORE2-OP<\/strong>\u00a0(for older persons).<\/li>\n\n\n\n
        3. Evaluate for risk modifiers (e.g., family history of premature CVD, specific conditions in women like gestational diabetes or pre-eclampsia).<\/li>\n\n\n\n
        4. Consider additional testing (e.g., for hypertension-mediated organ damage).<\/li>\n<\/ol>\n<\/li>\n\n\n\n
        5. Hypertension-Mediated Organ Damage (HMOD)<\/strong>: Screening for subclinical damage to the heart, brain, kidneys, and eyes is a key part of the initial workup.<\/li>\n<\/ul>\n\n\n\n

          4. Primary and Secondary Causes<\/strong><\/p>\n\n\n\n

          Understanding the underlying cause is crucial for effective management.<\/p>\n\n\n\n

            \n
          • Primary (Essential) Hypertension<\/strong>: This is the most common form, accounting for the vast majority of cases, where no single identifiable cause can be found.<\/li>\n\n\n\n
          • Secondary Hypertension<\/strong>: Accounts for approximately 10% of cases and has a discernible underlying cause.<\/li>\n<\/ul>\n\n\n\n

            Screening for Secondary Causes<\/strong>: The guidelines recommend comprehensive screening for secondary hypertension in specific groups:<\/p>\n\n\n\n

              \n
            • All adults diagnosed with hypertension before the age of 40<\/strong>.<\/li>\n\n\n\n
            • Exception<\/strong>: For obese young adults, screening for\u00a0obstructive sleep apnoea<\/strong>\u00a0should be the first step.<\/li>\n\n\n\n
            • Other common causes to consider include renal disease, primary aldosteronism, and drug-induced hypertension.<\/li>\n<\/ul>\n\n\n\n

              5. Management<\/strong><\/p>\n\n\n\n

              The 2024 guidelines advocate for a proactive and intensive, yet personalized, management strategy.<\/p>\n\n\n\n

              A. Lifestyle Modifications<\/strong><\/p>\n\n\n\n

              Lifestyle interventions are the cornerstone of management for all patients and should be initiated simultaneously with pharmacological treatment when indicated.<\/p>\n\n\n\n

                \n
              • Diet<\/strong>: Adopt a healthy diet (e.g., DASH-like), reduce sodium intake to <2 g\/day, and increase potassium intake.<\/li>\n\n\n\n
              • Exercise<\/strong>: Engage in regular aerobic and resistance training.<\/li>\n\n\n\n
              • Weight Management<\/strong>: Maintain a normal body-mass index.<\/li>\n\n\n\n
              • Other<\/strong>: Smoking cessation and limiting alcohol consumption.<\/li>\n<\/ul>\n\n\n\n

                B. Pharmacological Treatment: A Risk-Based Approach<\/strong><\/p>\n\n\n\n

                The decision to start medication is no longer based on BP alone but is integrated with overall CVD risk.<\/p>\n\n\n\n

                Category<\/td>CVD Risk<\/td>Management Strategy<\/td><\/tr><\/thead>
                Elevated BP<\/strong> (120-139\/70-89)<\/td>Low<\/strong> (10-year risk <5% or borderline 5-<10% without modifiers)<\/td>Lifestyle measures are recommended.<\/td><\/tr>
                Elevated BP<\/strong> (120-139\/70-89)<\/td>High<\/strong> (10-year risk \u226510%, or borderline with modifiers)<\/td>Lifestyle measures plus<\/strong> pharmacological treatment if BP remains \u2265130\/80 mmHg after 3 months.<\/td><\/tr>
                Hypertension<\/strong> (\u2265140\/90)<\/td>Any<\/td>Lifestyle and pharmacological treatment are recommended<\/strong>.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

                Key Treatment Principles<\/strong>:<\/p>\n\n\n\n

                  \n
                • Initial Therapy<\/strong>: For most patients, treatment should be initiated with a\u00a0single-pill combination<\/strong>\u00a0of two drugs.<\/li>\n\n\n\n
                • First-Line Agents<\/strong>: Recommended classes include\u00a0ACE inhibitors (ACEis), Angiotensin Receptor Blockers (ARBs), Dihydropyridine Calcium Channel Blockers (CCBs), and Diuretics<\/strong>.<\/li>\n\n\n\n
                • Treatment Target<\/strong>: The new target systolic BP for most adults on medication is\u00a0120-129 mmHg<\/strong>, provided it is well tolerated.<\/li>\n\n\n\n
                • The “ALARA” Principle<\/strong>: For patients who cannot tolerate the intensive target (e.g., those >85 years, frail, or with limited life expectancy), the goal is to achieve a BP that is\u00a0‘As Low as Reasonably Achievable’<\/strong>\u00a0(ALARA).<\/li>\n<\/ul>\n\n\n\n

                  C. Managing Resistant Hypertension<\/strong><\/p>\n\n\n\n

                  For patients with resistant hypertension, the guidelines recommend:<\/p>\n\n\n\n

                    \n
                  • Confirming true resistant hypertension and excluding secondary causes.<\/li>\n\n\n\n
                  • Optimizing therapy and adding\u00a0spironolactone<\/strong>\u00a0as the preferred fourth-line agent.<\/li>\n\n\n\n
                  • Referring to specialist centers and considering\u00a0renal denervation (RDN)<\/strong>\u00a0as a specialized, shared-decision option after thorough evaluation.<\/li>\n<\/ul>\n\n\n\n

                    <\/p>\n","protected":false},"excerpt":{"rendered":"

                    1. Definition & Classification The ESC has refined its classification system into three distinct categories based on standardized office blood pressure (BP) measurements. Category Office Systolic BP (mmHg) Office Diastolic BP … <\/p>\n","protected":false},"author":2,"featured_media":107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,13],"tags":[],"class_list":["post-102","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardiology","category-study"],"_links":{"self":[{"href":"https:\/\/heartimed.com\/index.php?rest_route=\/wp\/v2\/posts\/102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heartimed.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heartimed.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heartimed.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/heartimed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=102"}],"version-history":[{"count":1,"href":"https:\/\/heartimed.com\/index.php?rest_route=\/wp\/v2\/posts\/102\/revisions"}],"predecessor-version":[{"id":108,"href":"https:\/\/heartimed.com\/index.php?rest_route=\/wp\/v2\/posts\/102\/revisions\/108"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/heartimed.com\/index.php?rest_route=\/wp\/v2\/media\/107"}],"wp:attachment":[{"href":"https:\/\/heartimed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heartimed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heartimed.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}